Active Ingredient History
Ublituximab, sold under the brand name Briumvi, is an immunomodulator used for the treatment of multiple sclerosis. It is a CD20-directed cytolytic monoclonal antibody. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Multiple Sclerosis (approved 2022)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 3)
Lymphoma (Phase 1/Phase 2)
Lymphoma, B-Cell (Phase 1/Phase 2)
Lymphoma, B-Cell, Marginal Zone (Phase 2/Phase 3)
Lymphoma, Follicular (Phase 2/Phase 3)
Lymphoma, Large B-Cell, Diffuse (Phase 3)
Lymphoma, Large-Cell, Immunoblastic (Phase 1)
Lymphoma, Mantle-Cell (Phase 2/Phase 3)
Lymphoma, Non-Hodgkin (Phase 2)
Lymphoma, Primary Cutaneous Anaplastic Large Cell (Phase 1/Phase 2)
Medial Collateral Ligament, Knee (Phase 1)
Multiple Sclerosis (Phase 3)
Multiple Sclerosis, Relapsing-Remitting (Phase 2)
Neuromyelitis Optica (Phase 1)
Squamous Intraepithelial Lesions (Phase 1)
Waldenstrom Macroglobulinemia (Phase 1/Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
